Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease

Neuroscience

Volumn 41, Issue 2-3, 1991, Pages 507-523

  Mavridis, M ^a   Degryse, A D ^a   Lategan, A J ^a   Marien, M R ^a   Colpaert, F C ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPHYSIOLOGY; FEMALE; HISTOLOGY; LOCUS CERULEUS; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACOUSTIC STIMULATION; ANIMAL; CORPUS STRIATUM; DOPAMINE; ELECTROPHYSIOLOGY; FEMALE; LOCOMOTION; LOCUS COERULEUS; MOTOR ACTIVITY; NEURONS; PARKINSON DISEASE, SECONDARY; PHYSICAL STIMULATION; REFERENCE VALUES; SAIMIRI; SUBSTANTIA NIGRA; TREMOR;

EID: 0025853857     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(91)90345-O     Document Type: Article

References (93)

1. Evidence for norepinephrine mediated collateral inhibition of locus coeruleus neurons
2. Hyperactivity of remaining dopamine neurons after partial destruction of the nigrostriatal system in the rat
3. Preservation of dopamine release in the denervated striatum
4. Time course of adaptations in dopamine biosynthesis, metabolism and release following nigrostriatal lesions: implications for behavioural recovery from brain injury
5. Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain
6. Norepinephrine-dopamine interactions and behavior
7. Impulse conduction properties of noradrenergic locus coeruleus axons projecting to monkey cerebrocortex
8. Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases
9. Reversible dopamine depletion following unilateral infusion of MPTP in the common marmoset
10. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia
11. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
12. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
13. Adrenergic receptors in Parkinson's disease
14. Alterations in catecholamine neurons in the locus coeruleus in dementias of Alzheimer's and Parkinson's diseases
15. Dopamine in the Extrapyramidal Motor Function A Study Based upon the MPTP-Induced Primate Model of Parkinsonism"
16. Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra [proceedings].
17. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
18. 2-adrenoceptor antagonists
19. Aminergic systems in Alzheimer's disease and Parkinson's disease
20. Neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a model for Parkinson's disease and its therapy
21. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca Cynamolgus Fascicularis (Raffles)]
22. 2 adrenoceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat
23. The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motor activity in reserpine or α-methyl-p-tyrosine pretreated mice
24. The roles of noradrenaline and dopamine in contraversive circling behaviour seen after unilateral electrolytic lesions of the locus coeruleus
25. Variability and functional recovery in the n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonism in monkeys
26. Electrophysiological identification of neurons in locus coeruleus
27. Monoamine distribution in primate brain. V. Monoaminergic nuclei: anatomy, pathways and local organization
28. Clinical effectiveness of reserpine
29. Pathology of Parkinson's disease
30. Histochemical characterization of a neocortical projection of the nucleus locus coeruleus in the squirrel monkey
31. Central and peripheral catecholamine depletion by 1-methyl-4-phenyl-tetrahydropyridine (MPTP) in rodents
32. 1-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine-induced Parkinsonian syndrome inMacaca fascicularis: which midbrain dopaminergic neurons are lost?
33. Effects of clonidine, piperoxane and locus coeruleus lesion on the serotonergic and dopaminergic systems in raphe and caudate nucleus
34. Clonidine regularizes substantia nigra dopamine cell firing
35. The protective influence of the locus ceruleus on the blood-brain barrier
36. Partial lesions of the dopaminergic nigrostriatal system in the rat brain: biochemical characterization
37. Is Alzheimer's disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells?
38. Parkinsonism: onset, progression and mortality
39. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease. A critical analysis of the neurochemical evidence
40. Biochemical pathophysiology of Parkinson's disease
41. In vivo location and destruction of the locus coeruleus in the stumptail macaque (Macaca arctoides)
42. Fluorescence histochemistry of monoamine-containing cell bodies in the brain stem of the squirrel monkey (Saimiri sciureus). I. The locus coeruleus
43. Ascending projections of the locus coeruleus in the rat. II. Autoradiographic study
44. Brain microvessels are innervated by locus ceruleus noradrenergic neurons
45. The neutoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease
46. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
47. Use of reserpine in a neuropsychiatric hospital
48. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia
49. Behavioral effects of neuroleptics, apomorphine and amphetamine after bilateral lesions of the locus coeruleus in rats
50. MPTP neurotoxicity: an overview and characterization of phases of toxicity
51. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis
52. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey
53. 2 receptor agonists
54. Effects of locus coeruleus lesions on the release of endogenous dopamine in rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis
55. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase
56. Drug-induced experimental Parkinsonism
57. Dopaminergic supersensitivity after neuroleptics: time course and specificity
58. Beneficial effect of chronic treatment with ORG 2766 and α-MSH on impaired reversal learning of rats with bilateral lesions of the parafascicular area
59. Biochemical mapping of the noradrenergic ventral bundle projection sites: evidence for a noradrenergic-dopaminergic interaction
60. Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat
61. Effects of intraventricular 6-hydroxydopamine on dopaminergic innervation of striatum: histochemical and neurochemical analysis
62. The neuroanatomy of Alzheimer's disease
63. The MPTP-treated monkey: an animal model of Parkinson's disease
64. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease
65. Effects of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey
66. Cellular pathology in Alzheimer's and Parkinson's diseases
67. The interaction of clonidine with dopamine-dependent behaviour in rodents
68. Neuronal plasticity in the septal nuclei of the adult brain
69. Divergent axon collaterals of rat locus coeruleus neurons: demonstration by a fluorescent double labeling technique
70. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys
71. A perch for primate squeeze cages
72. Neuroanatomical correlates of spared or altered function after brain lesions in the newborn hamster
73. Recent physiological and pathophysiological aspects of parkinsonian movement disorders
74. Physiological properties of ascending locus coeruleus axons in the squirrel monkey
75. Parkinson's disease
76. Abnormal recrossing of retinotectal projections after early lesions in Syrian hamsters: a critical-age effect
77. Are glial cells targets of the central noradrenergic system? A review of the evidence
78. Collateral sprouting and reduced activity of the rat mesocortical dopaminergic neurons after selective destruction of the ascending noradrenergic bundles
79. Cell loss in the locus coeruleus in senile dementia of Alzheimer type
80. Mechanisms of supersensitivity and subsensitivity to sympathomimetic amines
81. Functional and structural observations on chronically reserpinized monkeys
82. Effects of environmental conditions on the psychological well-being of primates—review of the literature
83. Rapid recovery of function after partial denervation of the rat pineal gland suggests a novel mechanism for neural plasticity
84. Rapid recovery of pineal function after partial denervation: a possible role for heteroneural uptake of transmitter in modulating synaptic efficacy
85. Neurochemical events underlying continued function despite injury to monoaminergic systems
86. Clinical and pathological correlates of locus coeruleus pathology in Parkinson's diseases and Huntington's disease